Association Study between Treatment Response of Amisulpride and Dopamine D3 Receptor Gene Polymorphisms.
- Author:
Seung Gul KANG
1
;
Heon Jeong LEE
;
Seung Jae LEE
;
Tae Young CHOI
;
Jungmin WOO
;
Jihyun KIM
;
Sung Won JUNG
;
Bon Hoon KOO
;
Kwanghun LEE
;
Jeong Lan KIM
;
Ik Seung CHEE
;
Jonghun LEE
Author Information
1. Department of Psychiatry, Gil Medical Center, Gachon University School of Medicine, Incheon, Korea.
- Publication Type:Original Article
- Keywords:
Treatment response;
Amisulpride;
DRD3 gene;
Polymorphisms;
rs6280
- MeSH:
Alleles;
Dopamine*;
Genotype;
Humans;
Pharmacogenetics;
Polymorphism, Genetic;
Polymorphism, Single Nucleotide;
Receptors, Dopamine D3*;
Schizophrenia
- From:Journal of the Korean Society of Biological Psychiatry
2013;20(3):91-96
- CountryRepublic of Korea
- Language:Korean
-
Abstract:
OBJECTIVES: The aim of this study is to evaluate the association between rs6280 and rs905568 genetic polymorphism of DRD3 gene and the treatment response of amisulpride. METHODS: After six weeks treatment of amisulpride, 125 schizophrenia patients were interviewed based on the Positive and Negative Syndrome Scale (PANSS) and the Clinical Global Impression-Severity (CGI-S). The genotyping for rs6280 and rs905568 was performed using TaqMan single nucleotide polymorphism (SNP) genotyping assay. RESULTS: There was no significant difference in the frequency of genotype and allele of rs6280 between the responders and non-responders based on the total, positive, and general score of PANSS and CGI-S score. However, there was a significant association between this SNP and treatment response in the negative score of PANSS (chi2 = 5.23, p = 0.022). There was no significant association between rs905568 and the response in positive, negative, general, and total PANSS score and CGI-S score. CONCLUSIONS: This is the first positive association study between DRD3 gene and the treatment response of negative symptoms to amisulpride in Korean schizophrenia patients. A larger scale research on more SNP of the DRD3 gene will make a progress in the study of pharmacogenetics on the treatment response of the amisulpride.
